Cencora has entered into a strategic collaboration with Curant Rare to deliver an end-to-end commercialization solution for rare and orphan drug products. Leveraging Cencora’s global pharmaceutical logistics network and market access services alongside Curant Rare’s specialty pharmacy capabilities and omnichannel patient engagement tools, the partnership aims to streamline regulatory navigation, reduce time-to-therapy and enhance patient adherence. The integrated model provides real-world evidence analytics, pharmacovigilance support and tailored market access strategies, targeting an optimized patient journey for therapies addressing ultra-rare conditions. This collaboration positions Cencora to capture a growing share of the rare disease segment, projected to expand at a double-digit rate over the next five years due to increased orphan drug approvals and heightened payer focus on specialty product outcomes.

Cencora’s board has elected Ellen Cooper, Chairman, President and CEO of Lincoln Financial, as an independent director effective January 20, 2026. With over 25 years of financial services leadership—including roles as EVP and Chief Investment Officer at Lincoln, Global Head of Insurance Strategy at Goldman Sachs Asset Management and Chief Risk Officer at AEGON Americas—Ms. Cooper brings deep expertise in enterprise risk management, regulatory compliance and strategic capital allocation. Her appointment enhances board oversight of Cencora’s $300 billion annual revenue operations and supports the company’s ambition to expand its pharmaceutical solutions footprint globally. The addition underscores Cencora’s commitment to governance excellence as it pursues long-term sustainable growth in specialty logistics and clinical supply chain services.